Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer

NCT00316186 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00316186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00316186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-line Treatment of Chemonaive Subjects With Extensive Disease Small Cell Lung Cancer
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
May 31, 2009
Enrollment
33 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, small cell